Molecular glue drugs show promise as breakthrough pancreatic cancer treatment, driving industry dealmaking
By
Bloomberg
If you only eat one bagel today, this is the bagel.
Summary
Chemical biologist Gregory Verdine pioneered the concept of "molecular glues" — drugs that bind to disease-causing proteins inside cells and mark them for destruction. Despite initial skepticism, Revolution Medicines Inc. (which acquired one of Verdine's companies in 2018) has achieved breakthrough results with this approach, showing that one of its drugs doubled survival time for patients with aggressive pancreatic cancer. This success has sparked a surge in dealmaking and investment, positioning molecular glues as a potentially transformative new class of cancer therapeutics.
Key quotes
· 3 pulledEverybody told us this is crazy, that it would never work.
One of the biggest advances in pancreatic cancer in decades came out of a crazy idea born in a Harvard University lab.
Revolution Medicines Inc., which bought one of Verdine's companies in 2018, recently announced that one of its drugs doubled the typical survival time for patients with aggressive forms of the disease.
You might also wanna read
Molecular glue approach doubles survival time for pancreatic cancer patients in breakthrough trial
Chemical biologist Gregory Verdine developed a novel approach to fighting cancer by using "molecular glues" to bind disease-causing proteins
pasadenastarnews.com·1h ago
Career Opportunities at Verge Genomics
The article appears to be about job opportunities at Verge Genomics, a company focused on genomics research and biotechnology. While the spe
jobs.ashbyhq.com·3mo ago
Molecular glue approach doubles survival time for aggressive pancreatic cancer patients
Chemical biologist Gregory Verdine developed a novel approach to fighting cancer by using "molecular glues" to bind disease-causing proteins
pasadenastarnews.com·2h ago
Experimental pill daraxonrasib extends survival in advanced pancreatic cancer patients, study finds
Researchers reported that daraxonrasib, a novel experimental pill, helped patients with advanced pancreatic cancer live longer by blocking a
npr.org·3h ago
Experimental daraxonrasib pill nearly doubles survival time in advanced pancreatic cancer trial
A new experimental pill called daraxonrasib has shown promising results in extending survival for patients with advanced pancreatic cancer.
cnbc.com·5h ago
Daily pill daraxonrasib doubles survival in advanced pancreatic cancer, clinical trial shows
A clinical trial has shown that a daily pill called daraxonrasib can double survival time for patients with advanced pancreatic cancer, one
theguardian.com·5h ago